Mirtazapine, in orodispersible form, for patients with preoperative psychological distress: A pilot study

Wei-Han Chou , Feng-Sheng Lin , Chih-Peng Lin , Wen-Ying Lin , Jr-Chi Yie , Wei-Zen Sun
{"title":"Mirtazapine, in orodispersible form, for patients with preoperative psychological distress: A pilot study","authors":"Wei-Han Chou ,&nbsp;Feng-Sheng Lin ,&nbsp;Chih-Peng Lin ,&nbsp;Wen-Ying Lin ,&nbsp;Jr-Chi Yie ,&nbsp;Wei-Zen Sun","doi":"10.1016/j.aat.2015.12.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Perioperative psychological distress is associated with preoperative anxiety, depression, and postoperative pain. Mirtazapine is effective as an antidepressant, anxiolytic agent, and sleep enhancer. Moreover, mirtazapine can be made as orodispersible tablets with a fast onset for patients in nil per os status. This study is to determine whether mirtazapine can help psychologically distressed patients reduce perioperative anxiety, depression, and postoperative pain.</p></div><div><h3>Materials and methods</h3><p>Patients with preoperative psychological distress, undergoing major abdominal surgery, were inquired and assigned to two groups according to their own choice. In the treatment group, patients could choose to take orodispersible mirtazapine 30 mg at each night from Preoperative Day 0 to Postoperative Day 3. There was no other intervention in the nontreatment group. Hospital Anxiety and Depression Scale (HADS), Athens Insomnia Scale (AIS), and pain scores were accessed on the day before operation (Day 0), and on the 1<sup>st</sup> day (Day 2) and 3<sup>rd</sup> day (Day 4) after operation. We compared the HADS, AIS, and pain scores, and morphine consumptions between the two groups on a daily basis. Marginal regression models were fitted to our correlated longitudinal data alone with the generalized estimating equations method to estimate the population average effects of time-varying mirtazapine usage on the mean values of HADS, AIS, and pain scores, and daily morphine consumptions.</p></div><div><h3>Results</h3><p>From September 2007 to December 2008, 86 patients agreed to be enrolled and 79 of them completed the study. Propensity scores and multivariate analysis showed that mirtazapine reduced HADS scores of patients in 2 days. Trial results indicated that mirtazapine lowered the AIS day index and tended to decrease night index as well. Mirtazapine may reduce patients' morphine consumption, but this effect was not statistically significant (<em>p</em> = 0.2).</p></div><div><h3>Conclusion</h3><p>Mirtazapine helps reduce anxiety, depression, and insomnia scores for patients with perioperative psychological distress.</p></div>","PeriodicalId":87042,"journal":{"name":"Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists","volume":"54 1","pages":"Pages 16-23"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.aat.2015.12.002","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875459715001174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Background

Perioperative psychological distress is associated with preoperative anxiety, depression, and postoperative pain. Mirtazapine is effective as an antidepressant, anxiolytic agent, and sleep enhancer. Moreover, mirtazapine can be made as orodispersible tablets with a fast onset for patients in nil per os status. This study is to determine whether mirtazapine can help psychologically distressed patients reduce perioperative anxiety, depression, and postoperative pain.

Materials and methods

Patients with preoperative psychological distress, undergoing major abdominal surgery, were inquired and assigned to two groups according to their own choice. In the treatment group, patients could choose to take orodispersible mirtazapine 30 mg at each night from Preoperative Day 0 to Postoperative Day 3. There was no other intervention in the nontreatment group. Hospital Anxiety and Depression Scale (HADS), Athens Insomnia Scale (AIS), and pain scores were accessed on the day before operation (Day 0), and on the 1st day (Day 2) and 3rd day (Day 4) after operation. We compared the HADS, AIS, and pain scores, and morphine consumptions between the two groups on a daily basis. Marginal regression models were fitted to our correlated longitudinal data alone with the generalized estimating equations method to estimate the population average effects of time-varying mirtazapine usage on the mean values of HADS, AIS, and pain scores, and daily morphine consumptions.

Results

From September 2007 to December 2008, 86 patients agreed to be enrolled and 79 of them completed the study. Propensity scores and multivariate analysis showed that mirtazapine reduced HADS scores of patients in 2 days. Trial results indicated that mirtazapine lowered the AIS day index and tended to decrease night index as well. Mirtazapine may reduce patients' morphine consumption, but this effect was not statistically significant (p = 0.2).

Conclusion

Mirtazapine helps reduce anxiety, depression, and insomnia scores for patients with perioperative psychological distress.

米氮平,以或分散形式,对术前心理困扰患者:一项试点研究
围手术期心理困扰与术前焦虑、抑郁和术后疼痛有关。米氮平是一种有效的抗抑郁剂、抗焦虑剂和睡眠促进剂。此外,米氮平可制成非分散片,对无症状患者起效快。本研究旨在确定米氮平是否能帮助心理困扰患者减轻围手术期焦虑、抑郁和术后疼痛。材料与方法对腹部大手术术前存在心理困扰的患者进行问卷调查,根据患者的选择将患者分为两组。治疗组患者可选择术前第0天至术后第3天每晚口服或分散米氮平30 mg。未治疗组没有其他干预措施。分别于术前(第0天)、术后第1天(第2天)、第3天(第4天)进行医院焦虑抑郁量表(HADS)、雅典失眠量表(AIS)和疼痛评分。我们比较了两组患者的HADS、AIS和疼痛评分,以及每日吗啡用量。采用广义估计方程法对相关纵向数据拟合边际回归模型,以估计随时间变化的米氮平使用对HADS、AIS和疼痛评分平均值以及每日吗啡摄入量的总体平均影响。结果2007年9月至2008年12月,86例患者同意入组,其中79例完成研究。倾向评分和多变量分析显示,米氮平在2天内降低了患者的HADS评分。试验结果表明,米氮平降低AIS白天指数,并有降低夜间指数的趋势。米氮平可减少患者吗啡用量,但无统计学意义(p = 0.2)。结论米氮平可降低围手术期心理困扰患者的焦虑、抑郁和失眠评分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信